RxDoctor Payments Data

Brian Knopf, MD

Family Medicine · Lebanon, MONPI 1952306110

Payments from drug & device makers

$816in general payments, 2019–2025

Across 55 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$229
  • Pfizer$123
  • Amgen$85
  • Otsuka America Pharmaceutical, Inc.$52
  • Novo Nordisk$45
  • Sunovion Pharmaceuticals Inc.$44
  • plus $237 from 8 others

What the payments were for

  • Food & beverage$79898%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$816 in reported general payments places this provider in the 60th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$73,736
Medicare patients
250
Services billed
1,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate91$105,054
EliquisApixaban113$98,582
OzempicSemaglutide39$56,852
XareltoRivaroxaban48$42,037
MounjaroTirzepatide33$40,431
JardianceEmpagliflozin31$28,586
TrulicityDulaglutide13$23,453
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,675
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$14,242
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$11,417
Incruse ElliptaUmeclidinium Bromide23$11,042
SymbicortBudesonide/Formoterol Fumarate28$10,819
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$7,932
Breo ElliptaFluticasone/Vilanterol14$5,436
Omeprazole389$5,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$229$105,05491 claims
PfizerEliquis, Abrysvo$123$103,220132 claims
Lilly USA, LLCMounjaro, Trulicity$39$63,88446 claims
Novo NordiskOzempic$45$56,85239 claims
Boehringer IngelheimJardiance$40$28,58631 claims
AstraZenecaSymbicort$26$10,81928 claims
AbbVieSynthroid$30$2,12330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Lebanon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →